Coronary atherosclerotic heart disease, also referred to coronary heart disease (CHD), is a common type of cardiovascular disease and a major public concern in China (Bai and Wang, 2019). During the last decade, the death number of global cardiovascular disease has increased by 12.5%, and in 2017, cardiovascular disease accounts for one third of global human death (GBD, 2018). The trend of the prevalence of chronic diseases in China from 2018-2025 shows that the prevalence of CHD is still on the rise (from 1612.79/100,000-1895.91/100,000) (Cao et al., 2020). CHD is the most prevalent diseases and a main cause of hospitalization, mortality and healthcare expenditure (Zhang et al., 2019). Percutaneous coronary intervention (PCI) was a common treatment for CHD which were